Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

No association of the 5′ promoter region polymorphism of CYP17 gene with prostate cancer risk

Prostate Cancer and Prostatic Diseases volume 5, pages 28–31 (2002)Cite this article

Abstract

CYP17 gene encodes the enzyme cytochrome p450c17α, which mediates two steps in the steroid biosynthesis pathway. Steroid hormones are believed to play a key role in the etiology of prostate cancer. A polymorphic T→C transition in the 5′ promoter region of CYP17 creates an additional Sp1-type (CCACC box) promoter site (allele A2). We have evaluated the genotypic and allelic distribution of this polymorphism among 92 prostate cancer patients in order to assess risk by comparison with a population-based series of 200 healthy individuals from Brazil. Our results provide no evidence for an association between prostate cancer risk and CYP17 T/C polymorphism.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. INCA (Instituto Nacional do Câncer) 2000 http://www.inca.org.br/ accessed October 2000

  2. Ilic M, Vlajinac H, Marinkovic J. . Case–control study of risk factors for prostate cancer. Br J Cancer 1996 74: 1682–1686.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Daviglus ML et al. Dietary betacarotene, vitamin C, and risk of prostate cancer: results from the Western Electric Study. Epidemiology 1996 7: 472–477.

    Article  CAS  PubMed  Google Scholar 

  4. Lumey LH. . Prostate cancer and smoking: a review of case–control and cohort studies. Prostate 1996 29: 249–260.

    Article  CAS  PubMed  Google Scholar 

  5. Van der Gulden JW, Kolk JJ, Verbeek AL. . Prostate cancer and work environment. J Occup Med 1992 34: 402–409.

    CAS  PubMed  Google Scholar 

  6. Parkin DM, Pisani P, Ferlay J. . Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993 54: 594–606.

    Article  CAS  PubMed  Google Scholar 

  7. Neuhausen SL, Skolnick MH, Cannon-Albright L. . Familial prostate cancer studies in Utah. Br J Urol 1997 79: Suppl 1 15–20.

    Article  PubMed  Google Scholar 

  8. Wilding G. . The importance of steroid hormones in prostate cancer. Cancer Surv 1992 14: 113–130.

    CAS  PubMed  Google Scholar 

  9. Nomura AMY, Kolonel LN. . Prostate cancer: a current perspective. Am J Epidemiol 1991 13: 200–227.

    CAS  Google Scholar 

  10. Ross RK, Paganini-Hill A, Henderson BE. . The etiology of prostate cancer: what does the epidemiology suggest? Prostate 1983 4: 333–344.

    Article  CAS  PubMed  Google Scholar 

  11. Waterman MR, Keeney DS. . Genes involved in androgen biosynthesis and the male phenotype. Horm Res 1992 38: 217–221.

    Article  CAS  PubMed  Google Scholar 

  12. López-Otín C, Diamandis EP. . Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev 1998 19: 365–396.

    PubMed  Google Scholar 

  13. Picado-Leonard J, Miller WL. . Cloning and sequence of the human gene for P450c17 (steroid 17 -hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA 1987 6: 439–448.

    Article  CAS  PubMed  Google Scholar 

  14. Carey AH et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17 Hum Mol Genet 1994 3: 1873–1876.

    Article  CAS  PubMed  Google Scholar 

  15. Kadonada JT et al. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 1987 51: 1079–1090.

    Article  Google Scholar 

  16. Kristensen VN et al. CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp1. Cancer Res 1999 59: 2825–2828.

    CAS  Google Scholar 

  17. Carvalho-Silva DR, Santos FR, Rocha J, Pena SDJ. . The phylogeography of Brazilian Y-chromosome lineages. Am J Hum Genet 2001 68: 281–286.

    Article  CAS  PubMed  Google Scholar 

  18. Lunn RM, Bell DA, Mohler JL, Taylor JA. . Prostate cancer risk and polymorphism in 17α hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999 20: 1727–1731.

    Article  CAS  PubMed  Google Scholar 

  19. Feigelson HS et al. Cytochrome P450c17α gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res 1999 59: 3908–3910.

    CAS  PubMed  Google Scholar 

  20. Wadelius MA et al. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999 9: 635–639.

    CAS  PubMed  Google Scholar 

  21. Huang J et al. Possible association of CYP17 gene polymorphisms with the onset of rheumatoid arthritis. Clin Exp Rheumatol 1999 17: 721–724.

    CAS  PubMed  Google Scholar 

  22. Habuchi T et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000 15: 5710–5713.

    Google Scholar 

  23. Gsur A et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000 87: 434–437.

    Article  CAS  PubMed  Google Scholar 

  24. Feigelson HS et al. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 1997 57: 1063–1065.

    CAS  PubMed  Google Scholar 

  25. Hamajima N et al. No association of the 5′ promoter region polymorphism of CYP17 with breast cancer risk in Japan. Jpn J Cancer Res 2000 91: 880–885.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge the Hematology–Hemotherapy Center of the State University of Campinas for allowing the access to the blood donors. AS and MLR are supported by fellowships from Fundo de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Brazil.

Author information

Authors and Affiliations

  1. Centro de Biologia Molecular e Engenharia Genética, Universidade Estadual De Campinas, Sáo Paulo, Brazil

    A dos Santos, M L Ribeiro & C Hackel

  2. Departamento de Genética Médica, Faculdade de Ciências Médicas, CP 6111 Universidade Estadual de Campinas, Sáo Paulo, Brazil

    C Hackel

  3. Serviço de Urologia, Faculdade de Medicina de Sáo José do Rio Preto, Sáo Paulo, Brazil

    J C Mesquita

  4. Hemocentro de São José do Rio Preto, Sáo Paulo, Brazil

    A B Carvalho-Salles

Authors
  1. A dos Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M L Ribeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J C Mesquita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A B Carvalho-Salles
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Hackel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Hackel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

dos Santos, A., Ribeiro, M., Mesquita, J. et al. No association of the 5′ promoter region polymorphism of CYP17 gene with prostate cancer risk. Prostate Cancer Prostatic Dis 5, 28–31 (2002). https://doi.org/10.1038/sj.pcan.4500550

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500550

Keywords

This article is cited by

Search

Advanced search

Quick links